DK0952148T3 - Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater - Google Patents

Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater

Info

Publication number
DK0952148T3
DK0952148T3 DK99302282T DK99302282T DK0952148T3 DK 0952148 T3 DK0952148 T3 DK 0952148T3 DK 99302282 T DK99302282 T DK 99302282T DK 99302282 T DK99302282 T DK 99302282T DK 0952148 T3 DK0952148 T3 DK 0952148T3
Authority
DK
Denmark
Prior art keywords
cyclobutylaryloxyarylsulfonylaminohydroxamic
acid derivatives
arthritis
chem
cancer
Prior art date
Application number
DK99302282T
Other languages
Danish (da)
English (en)
Inventor
Lawrence Alan Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0952148T3 publication Critical patent/DK0952148T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99302282T 1998-04-10 1999-03-25 Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater DK0952148T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8139298P 1998-04-10 1998-04-10

Publications (1)

Publication Number Publication Date
DK0952148T3 true DK0952148T3 (da) 2004-09-20

Family

ID=22163854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99302282T DK0952148T3 (da) 1998-04-10 1999-03-25 Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater

Country Status (10)

Country Link
US (1) US6156798A (fr)
EP (1) EP0952148B1 (fr)
JP (1) JP3626366B2 (fr)
AT (1) ATE266634T1 (fr)
BR (1) BR9901250A (fr)
CA (1) CA2268484C (fr)
DE (1) DE69917124T2 (fr)
DK (1) DK0952148T3 (fr)
ES (1) ES2220004T3 (fr)
PT (1) PT952148E (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336840A (en) * 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2001070677A1 (fr) * 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Dérivés de bicyxloalkyle à pontage à substitution sulphonamido
EP1191024A1 (fr) * 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines et leur utilisation comme inhibiteurs de métalloproteinases
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
WO2003000194A2 (fr) 2001-06-21 2003-01-03 Pfizer Inc. Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2003045433A1 (fr) * 2001-11-29 2003-06-05 Nippon Organon K.K. Remedes contre l'insuffisance cardiaque
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2003055851A1 (fr) * 2001-12-27 2003-07-10 Sumitomo Pharmaceuticals Company, Limited Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active
BR0312943A (pt) * 2002-07-17 2005-07-12 Warner Lambert Co Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
WO2004006913A1 (fr) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combinaison d'un inhibiteur allosterique de la metalloproteinase matricielle 13 avec un celecoxib ou valdecoxib
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
EP1998760A2 (fr) * 2006-03-30 2008-12-10 James E. Summerton Compositions outils oncologiques et procédés d'utilisation pour détecter et traiter des tumeurs
AU2007350326A1 (en) * 2007-03-30 2008-10-09 James E. Summerton Non-peptidic molecules for detecting and treating tumors
EP2119690A1 (fr) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Composants sélectifs MMP radiomarqués
EP3812387A1 (fr) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de protéine kinase hétérocycliques
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR20000068248A (ko) * 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
AU736134B2 (en) * 1996-10-16 2001-07-26 Wyeth Holdings Corporation Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
CA2299355C (fr) * 1997-08-08 2005-09-27 Pfizer Products Inc. Derives de l'acide aryloxyarylsulfonylamino hydroxamique

Also Published As

Publication number Publication date
BR9901250A (pt) 2000-05-16
PT952148E (pt) 2004-09-30
CA2268484C (fr) 2006-02-07
JPH11322705A (ja) 1999-11-24
JP3626366B2 (ja) 2005-03-09
EP0952148B1 (fr) 2004-05-12
ATE266634T1 (de) 2004-05-15
DE69917124T2 (de) 2005-05-12
EP0952148A1 (fr) 1999-10-27
ES2220004T3 (es) 2004-12-01
US6156798A (en) 2000-12-05
CA2268484A1 (fr) 1999-10-10
DE69917124D1 (de) 2004-06-17

Similar Documents

Publication Publication Date Title
DK0952148T3 (da) Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater
MY120235A (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
NO941662D0 (no) Benzofuranyl- og -tiofenyl-alkankarboksylsyrederivater
GB9801690D0 (en) Therapeutic agents
NO940038D0 (no) Arylsulfonamido-substituerte hydrokamsyrer
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
DE69814375D1 (de) Fungizide trifluoromethylalkylamino-triazolopyrimidine-derivate
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
PT1109812E (pt) Pirrolobenzodiazepinas
ES2151156T3 (es) Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados.
PT993447E (pt) Processo para a preparacao de benzenossulfonato de amlodipina
FI972074A0 (fi) Akrylamidderivat och foerfarande foer framstaellning daerav
DK0747392T3 (da) Dobbeltvirkende inhibitorer indeholdende 1,2-diazepiner
ATE131154T1 (de) Phenylalkan(en)säuren.
GR3033350T3 (en) Use of Beta-aminopropionic acid derivatives as fungicides
DZ1724A1 (fr) Nouvelles azétidinones substituées comme agents anti-inflammatoires et anti-dégénérescence.
ATE280767T1 (de) Antidiabetische thiazolidindione und ihre herstellung
ATE114154T1 (de) Thienotriazolodiazepine und ihre pharmazeutische verwendung.
ES2053809T3 (es) Derivados de ciclopropano.
ID26210A (id) Proses pemurnian turunan sefalosporin
RU2001120358A (ru) Применение ингибиторов натрий-водород-антипортера для получения лекарственного средства для ингибирования обусловленных возрастом дисфункций органов, обусловленных возрастом заболеваний и для продления жизни
DK0625520T3 (da) Thiazolotriazol- og thiazolodiazolderivater med fungicid aktivitet
ECSP982620A (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
GEP19971039B (en) Method for production of acrylic acid